Biocryst Pharmaceuticals will present new clinical trial and real-world data on its treatments for hereditary angioedema (HAE) at this year’s American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, the company announced. The data include six abstracts reporting updated findings on Orladeyo (berotralstat), an approved oral…